N-Acetyl-L-Cysteine
Squamous Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research InstitutePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Squamous Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Qilu Hospital of Shandong University | Phase 4 | BBB |
Carboplatin zhang yi | Phase 3 | BBB |
Docetaxel Shanghai JMT-Bio Inc. | Phase 3 | BBB |
ETOPOSIDE Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
View all 45 →
Same molecule, other indications
N-Acetyl-L-Cysteine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →